Karyopharm Therapeutics Inc.(KPTI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Karyopharm Therapeutics Inc. (KPTI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KPTI at 15.1/100 on a 32-signal composite quality model, placing it at rank #2,858 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (0.3) and institutional flow (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Karyopharm Therapeutics Inc. reports quarterly revenue of $33.4M, net income of $-67.0M. Top institutional holders of KPTI by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., ACORN CAPITAL ADVISORS, based on the most recent SEC filings. KPTI trades on the Nasdaq exchange and files with the SEC under CIK 1503802. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KPTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Karyopharm Therapeutics Inc. directly from SEC EDGAR.